Overview
Location
South Korea, Seoul
Investors 2
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 20, 2023 | Premier Partners | premierpartners.co.kr |
Mentions in press and media 2
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 25, 2024 | Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD) | SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the tr... |
Reviews 0
FAQ about 온코닉테라퓨틱스
Who has invested in 온코닉테라퓨틱스?
Parsers VC lists 2 investors of 온코닉테라퓨틱스, among them Premier Partners.
What has the press written about 온코닉테라퓨틱스?
Parsers VC has collected 2 articles mentioning 온코닉테라퓨틱스, among them “Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)” (Apr 25, 2024).
Is 온코닉테라퓨틱스 still active?
Yes, 온코닉테라퓨틱스 is active; its latest activity on Parsers VC dates from May 29, 2024.